Prothena will cut 63% of its workforce and evaluate a “range of business options.” Elsewhere, Zealand revealed data for a ...

In May, the company announced the failure of the monoclonal antibody birtamimab to improve mortality in a phase 3 trial of ...

Prothena Corp shares climbed 5% in after-hours trading on Friday after the company said it expects to reduce its 2025 net ...

Why California wants to stop 23andMe's sale to former CEO How a Peninsula company is brewing cheaper Narcan in the U.S. How a ...

Bristol Myers Squibb is teaming up with Prothena in a high-stakes lab dance to tackle Alzheimer’s disease with two ...

The U.K.-based biotech is set to enter mid-stage studies for its depression drug this year, while two other GABAA modulators ...

Prothena Corporation plc (NASDAQ:PRTA) is among the best NASDAQ stocks under $50 to buy. Roche, a partner of Prothena ...

Roche and Prothena are advancing Prasinezumab to Phase 3 for Parkinson’s despite mixed Phase 2 results. Click here to read an ...

Roche has announced that it will be advancing its Prothena-partnered investigational Parkinson’s disease (PD) drug ...

Detailed price information for Jasper Therapeutics Inc. (JSPR-Q) from The Globe and Mail including charting and trades.

Basel: Roche has announced its decision to proceed with Phase III development of prasinezumab, an investigational ...